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 Abstract  
Background: There is a need for screening and brief assessment instruments to identify primary 
care patients with substance use problems. This study’s aim was to examine the performance of a 
two-step screening and brief assessment instrument, the TAPS Tool, compared to the WHO 
ASSIST. 
Methods: Two thousand adult primary care patients recruited from five primary care clinics in 
four Eastern US states completed the TAPS Tool followed by the ASSIST. The ability of the 
TAPS Tool to identify moderate- and high-risk use scores on the ASSIST was examined using 
sensitivity and specificity analyses.      
Results: The interviewer and self-administered computer tablet versions of the TAPS Tool 
generated similar results. The interviewer-administered version (at cut-off of 2), had acceptable 
sensitivity and specificity for high-risk tobacco (0.90 and 0.77) and alcohol (0.87 and 0.80) use. 
For illicit drugs, sensitivities were >0.82 and specificities >0.92.  The TAPS (at a cut-off of 1) 
had good sensitivity and specificity for moderate-risk tobacco use (0.83 and 0.97) and alcohol 
(0.83 and 0.74). Among illicit drugs, sensitivity was acceptable for moderate-risk of marijuana 
(0.71), while it was low for all other illicit drugs and non-medical use of prescription 
medications. Specificities were 0.97 or higher for all illicit drugs and prescription medications.  
Conclusions: The TAPS Tool identified adult primary care patients with high-risk ASSIST 
scores for all substances as well moderate-risk users of tobacco, alcohol, and marijuana, although 
it did not perform well in identifying patients with moderate-risk use of other drugs or non-
medical use of prescription medications.  The advantages of the TAPS Tool over the ASSIST are 
its more limited number of items and focus solely on substance use in the past 3 months. 
Keywords: Substance abuse screening, substance abuse assessment, primary care, ASSIST 
 1. Introduction 
 In recognition of the health problems associated with substance use and the need for an 
efficient approach to screen and assess substance-using individuals in primary care settings, the 
World Health Organization (WHO) developed the Alcohol, Smoking and Substance Involvement 
Screening Test (WHO ASSIST Working Group, 2002). The ASSIST consists of seven questions 
regarding each of 10 classes of substances and a question about drug injection. Items cover 
lifetime use and frequency of use in the past-3 months as well as various problems associated 
with the use of these substances. The ASSIST was found to have good concurrent, construct, and 
discriminant validity among a sample of 1,047 primary care and drug treatment patients in six 
countries spanning five continents (Humeniuk et al., 2008). Substance-specific involvement 
scores were developed to separate respondents into low-, moderate-, and high-risk categories for 
each substance. In developing the ASSIST, it was thought that the moderate-risk category, in 
particular, would help to identify individuals who otherwise might go undetected in health care 
settings (Humeniuk et al., 2008), while those with high risk scores were appropriate for referral 
to specialist addiction treatment services. A moderate-level substance risk score on the ASSIST 
was subsequently used as an inclusion criterion in a multi-site study of brief intervention in 
primary care (Humeniuk et al., 2012), that demonstrated the utility of the ASSIST in providing 
actionable data to triage patients to particular interventions.   
  Although the ASSIST has subsequently been studied across a variety of diverse 
populations, including adults with first-episode psychosis (Hides et al., 2009) and adolescents 
(Gryczynski et al., 2014), its widespread implementation has been hampered by the instrument’s 
length (requiring 5 to 15 minutes to administer) and complex scoring system (Ali et al., 2013; 
McNeely et al., 2014). In order to overcome these barriers to adoption, a computerized version of 
the full ASSIST that can be self-administered and scored automatically has been developed 
(Kumar, Cleland, Gourevitch et al., 2016; McNeely et al., 2016; Wolf & Shi, 2015). In addition, 
Ali and colleagues (2013) developed a short version of the ASSIST, termed the ASSIST-Lite, 
based on factor and item-response theory analyses of pooled data from previous validation 
studies of the ASSIST. This shortened version of the ASSIST has 3 items each for tobacco, 
cannabis, stimulants, sedatives, and opioids and 4 items for alcohol. The first item for each 
substance asks about any use in the past 3 months. Individuals who respond ‘yes’ to use of a 
substance are administered two (or for alcohol, three) subsequent items specific to that 
substance.  For tobacco, the two items were drawn from the Heaviness of Smoking Index (Diaz 
et al., 2005) and the Fagerström Tolerance Questionnaire (Tate & Schmitz, 1993), not the 
original ASSIST, and ask if the respondent smoked 10 or more cigarettes/day and if they smoked 
within 30 minutes of waking.  For the non-tobacco substances, the items are drawn from the 
ASSIST and vary depending on the substance.  These items query loss of control (alcohol and 
opioids), concern expressed by others (alcohol, opioids, cannabis, sedatives, stimulants), urge to 
use (cannabis and sedatives), and frequency of using (i.e., weekly or greater; stimulants). 
Participants reporting use of alcohol receive an additional item that asks about frequency of 
having 4 (for women) or 5 (for men) more drinks on a single occasion. Scoring was also 
simplified such that a score of 2 or greater for all substances except alcohol (which required a 
score of 3) yielded an acceptable level of diagnostic accuracy for identifying DSM-IV substance 
dependence.   
 The National Drug Abuse Treatment Clinical Trials Network launched a multi-site trial 
examining the validity of a two-step screening and brief assessment for substance use termed the 
Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool among 2,000 
adults enrolled in five primary care clinics across 4 states in the Eastern US (McNeely et al., 
2016). The TAPS Tool is a two-step screening (TAPS-1) and brief assessment (TAPS-2) 
instrument. The TAPS-1 was adapted from the NIDA Quick Screen v 1.0 (NIDA, 2016) and the 
TAPS-2 was based on the ASSIST-Lite (Ali et al., 2013) and modified for the US context (as 
described below). The TAPS Tool in both self-administered tablet computer (iPad) and 
interviewer-administered versions was compared  to a number of criterion measures, including 
the DSM-5 SUD criteria, the AUDIT-C, Fagerström Tolerance Questionnaire, and the ASSIST 
(Wu et al., 2016).  The primary analysis of the trial examined the performance of the TAPS Tool 
using the DSM-5 criteria as the gold standard (McNeely et al., 2016). The present paper is the 
first report on the concurrent validity of a modified version of the ASSIST-lite (i.e., the TAPS 
Tool) relative to the ASSIST. 
2. Methods 
 The study’s methods have been reported in detail elsewhere (Wu et al., 2016). In brief, 
2,000 adult primary care patients participated from August 2014-April 2015 at five primary care 
sites in four Eastern US states, including a Federally Qualified Health Center in Baltimore, MD, 
two practices in Kannapolis, NC, a public hospital clinic in New York City, and a University-
based primary care clinic in Richmond, VA (McNeely et al., 2016). Eligibility criteria were 
intentionally broad and included being a primary care patient of at least 18 years of age and 
being at the clinic for a medical visit on the day of recruitment. Patients who did not understand 
spoken English, were physically unable to use the iPad, or had already participated in the study 
were excluded. Willing patients meeting eligibility criteria provided verbal informed consent to 
Research Assistants (RAs) after reviewing an IRB-approved consent form. 
 The order of administration of the self-administered tablet computer version or 
interviewer-administered TAPS Tool was determined by an electronic data capture system, 
which randomized participants in a counterbalanced order, such that 50% of the participants 
were first administered the TAPS Tool by the RA followed by self-administration of the TAPS 
Tool on a tablet computer (iPad). In order to accommodate low-literacy patients, the tablet 
included an optional computer-assisted audio self-interview that read questions and response 
options out loud. The other 50% of the participants were administered the TAPS Tool in the 
reverse order. After both formats of the TAPS Tool were completed, the RA then administered 
criterion measures, including the ASSIST, to each participant. The RA provided participants 
with $20 after completion of the measures.  
2.1 Measures 
2.1.1 TAPS Tool 
As shown in Figure 1, the TAPS-1 screen inquires about past 12-month frequency of four 
substance classes: tobacco, alcohol (binge drinking in excess of 5 drinks/day for men or 4 
drinks/day for women); illicit drugs (including marijuana, cocaine methamphetamine, heroin); 
and non-medical use of prescription medications (including opioids, stimulants, and sedative-
hypnotics). There are five possible response categories that range from “never” to “daily or 
almost daily.” Any response other than “never” is considered a positive screen and leads to 
administration of the TAPS-2.  
The TAP-2 (shown in Figure 2), in contrast to the ASSIST and in keeping with the 
format of the ASSIST-Lite, has three items for each substance (four for alcohol) and a binary 
(yes/no) rather than an ordinal response format. The TAPS-2 was modified from the ASSIST-lite 
by adapting the ASSIST-lite for the US context by clarifying language (e.g., replacing cannabis 
with marijuana), replacing the Australian guideline of more than 4 drinks for both men and 
women with the NIAAA-recommended gender-specific variant (5+ for men and 4+ for women), 
and creating separate items for prescription opioids and prescription stimulants in order to 
separate them from their illicit counterparts (Wu et al., 2016).  
The TAPS-2 asks about past 3 month use of tobacco, alcohol, three classes of illicit drugs 
(marijuana, stimulants [cocaine, methamphetamine], and heroin), three classes of non-medical 
use of prescription medications (stimulants, opioids, and sedative-hypnotics), and ‘other’ drugs 
using a yes/no format. If the response is ‘no,’ the subsequent questions for that substance class 
are skipped.  When the answer is ‘yes’ to any past 3 month use, the participant receives 2 follow-
up items (3 for alcohol) specific to that substance class.   
Possible scores on the TAPS Tool for tobacco and each class are 0, 1, 2 or 3. For alcohol, 
the possible scores are 0, 1, 2, 3 or 4 (0 = no use; 1 = use but no problems; >1 = use plus one 
addition point for each problem per substance). Because the parent study was planned to assess 
the validity of the complete TAPS tool, which is the combination of TAPS-1 and TAPS-2, 
participants were asked to respond to all TAPS-2 questions even if their answers on the TAPS-1 
indicated no use in the prior 12 months. If the participant indicated never using a substance in the 
past 12 months on TAPS-1, but reported use in the past 3 months on TAPS-2, the combined 
TAPS Tool score is 0 for the present analysis (because when the TAPS Tool will be used in 
clinical practice, patients denying use in the past 12 months on the TAPS-1 would not be 
administered the TAPS 2). Otherwise the combined TAPS Tool score is the TAPS-2 score. 
 
2.2 Criterion Measure: ASSIST Version 3.0  
The ASSIST 3.0 (Humeniuk et al., 2008) consists of seven questions that are scored for 
each of 10 drug classes (tobacco, alcohol, cannabis, cocaine, amphetamine-type stimulants, 
inhalants, sedatives, hallucinogens, opioids, and other drugs). In addition, an eighth question 
(unscored) inquires about injection drug use. Only those who endorse any lifetime use in the first 
question for each substance category are then asked subsequent items for that substance. 
Questions 2 through 5 refer to the past 3-month period for each substance category and include 
questions on the frequency of use, cravings, problems associated with use, and failure to fulfill 
normal role expectations. Response categories for these items are: never, once or twice only, 
monthly, weekly, and daily/almost daily. Questions 6 and 7 (regarding others expressing concern 
over the patient’s use of the substance and the patient’s inability to control or stop using) are 
trinary items (Never; Yes, but not in the past 3 months; and Yes, in the past 3 months). The 
substance-specific score is obtained by adding the item scaling weights (as per the WHO scoring 
manual) on items 2 through 7 (WHO, 2016). Substance-specific scores (except for alcohol) are 
divided into low (0-3), moderate (4-26), and high risk (≥27). Alcohol risk categories are low (0-
10), moderate (11-26), and high (≥27).  
2.3 Statistical Analysis 
This study reports a preplanned secondary analysis from a multi-site study whose primary 
aim was to examine the TAPS Tool vs. the DSM-5 SUD criteria (McNeely et al., 2016). In this 
secondary analysis, the TAPS Tool substance specific scores for those participants who were 
positive on the TAPS-1 screen, were compared to ASSIST substance specific involvement scores 
corresponding to moderate-risk and high-risk use, with the ASSIST serving as the reference 
standard measure.  Because the TAPS-2, in contrast to the ASSIST-lite, separates the items for 
prescription stimulants and illicit stimulants (cocaine and methamphetamine) and the 
prescription opioids and heroin, analyses were conducted for each of the TAPS-2 items 
separately and then by combining illicit and prescription and illicit stimulants into a stimulant 
category and prescription opioids and heroin into an opioid category. Interviewer-administered 
and self-administered tablet computer versions of the TAPS-2 were examined. Sensitivity, 
specificity, and the positive and negative predictive values (PPV and NPV) were calculated.  The 
sensitivity and the specificity represent the proportion of patients whose ASSIST severity score 
categories (high risk or moderate risk and above) were correctly identified by the TAPS Tool 
cut-points and the proportion of patients who do not have a moderate or high risk ASSIST score 
and who have a negative TAPS Tool score (i.e., below the cut-points) respectively. The PPV 
represents the proportion of patients above the cut-points on the TAPS Tool who had a high or 
moderate risk and above score on the ASSIST, while the NPV shows the proportion of patients 
who test negative on the TAPS tool who do not have a high or moderate risk or above score on 
the ASSIST. Receiver operator characteristic (ROC) curves were computed and the area under 
each curve (AUC) was examined (Hanley & McNeil, 1982). The cut-point on the TAPS Tool 
was based on maximizing the AUC. In some cases (as shown in Table 2 and 3), in which the 
AUCs were quite similar but the marginally higher value would have resulted in a different cut-
point than the other substances, the cut-point matching the other substances was chosen in order 
to simplify interpretation of the test by primary care providers. Excellent discrimination was 
considered an AUC of >.90, good discrimination was considered an AUC of > 0.8, acceptable 
discrimination was considered >0.7, while an AUC of < 0.7 was considered poor discrimination 
(Hanley & McNeil, 1982). Wilson score 95% confidence intervals (CIs) were calculated for all 
estimates and all analyses were conducted in SAS® version 9.3.  
3. Results 
3.1 Participants.   
           The demographic characteristics of the 2,000 participants are shown in Table 1. Their 
mean (SD) age was 46.0 (14.7) and 56.2% of the sample were women. Slightly more than half 
were African American (55.6%), a third were White (33.4%) and 11.7% were Hispanic. The 
lifetime and past three month frequencies of substance use and the ASSIST risk categories (low, 
medium, high) by substance are shown in Table 2. 
3.2 Interviewer and Self-administered tablet computer versions.  
           The mean (SD) time to complete the TAPS Tool interviewer-administered version was 
2.39 (1.01) minutes and to complete the self-administered version was 4.47 (2.56) minutes. We 
did not assess the time to complete the ASSIST.  
The optimal cut-points on the TAPS Tool for detecting “high risk” and “moderate risk or 
higher” on the ASSIST were 2 and 1, respectively. Table 3 shows the sensitivity, specificity, 
PPV, NPV, and AUC for the interviewer-administered TAPS Tool, while Table 4 presents 
results for the self-administered tablet computer TAPS-2. These two formats for TAPS Tool 
administration had small differences in sensitivity, specificity, PPV, NPV, and AUC. Sensitivity 
exceeded 0.77 for all substance classes for detecting high risk ASSIST thresholds, except for 
prescription stimulants, prescription opioids, and prescription sedatives (because, as indicated in 
the methods section above, in contrast to the TAPS-2, the ASSIST combines prescription 
stimulants and illicit stimulants into a single item and heroin and prescription opioids into a 
single item). Specificities also exceeded 0.75 for all substances for detecting high risk with the 
exception of prescription stimulants. Given the similarities in their properties, for simplicity 
below we present in detail the properties of the interviewer-administered TAPS Tool. 
3.3 Identification of high-risk ASSIST scores from the Interviewer-administered TAPS Tool 
(Table 3).  
            The interviewer-administered TAPS Tool had good sensitivity and specificity for high 
risk use of tobacco (0.90 and 0.77, respectively) and alcohol (0.87 and 0.80, respectively). For 
illicit drugs, sensitivity ranged from a low of 0.82 for heroin to a high of 0.96 for marijuana.  For 
non-medical use of prescription drugs, sensitivities were lower.  For prescription opioids, 
sensitivity was 0.41. As described above, the ASSIST has a single item that combines heroin and 
prescription opioid use. Therefore, the single ASSIST opioid item was compared to the 
combined heroin and prescription opioid items on the TAPS Tool which yielded a sensitivity of 
0.92. The prescription stimulant and sedative items had very low sample size with high risk 
scores on the ASSIST for non-medical use of these medications (ns=4 and 8, respectively). 
Specificities exceeded .91 for all illicit substances.  PPVs for tobacco and alcohol were 0.20 and 
0.13, respectively.  PPVs for illicit substances ranged from 0.70 for heroin to 0.14 for marijuana. 
Finally, NPVs exceeded 0.99 for alcohol, tobacco, illicit substances and use of non-prescription 
medications.    
3.4 Identification of moderate risk ASSIST scores from the Interviewer-administered TAPS Tool 
(Table 2).   
              The interviewer-administered TAPS Tool had good sensitivity and specificity for 
identification of moderate risk tobacco use (0.83 and 0.97, respectively) and good sensitivity and 
acceptable specificity for alcohol (0.83 and 0.74, respectively). Among illicit drugs, sensitivity 
was acceptable for marijuana (0.71), while for all other illicit drugs and prescription medications, 
it was low (ranging from 0.28 for prescription opioids to 0.47 for sedatives).  In contrast, 
specificities were uniformly high, ranging at or exceeding 0.97 for all illicit drugs and 
prescription medications.  PPVs for tobacco and alcohol were .96 and .34, respectively.  PPVs 
for illicit and non-medical use of prescription drugs ranged from .42 for prescription stimulants 
to .93 for heroin. Finally, NPVs exceeded 0.87 for tobacco, alcohol, illicit drugs and non-medical 
use of prescription medications.  
4. Discussion 
The present study examined the concurrent validity of the TAPS Tool (a modified 
version of the ASSIST-Lite) in comparison to the full WHO ASSIST as part of a large, multi-site 
study in Eastern US primary care patients. The TAPS Tool was found to have favorable 
sensitivity and specificity at a cutpoint of 2 to detect high risk use of tobacco, alcohol, marijuana, 
stimulants (prescription and cocaine/methamphetamine combined) and opioids (prescription 
opioids  and heroin combined).  
The TAPS Tool at a cutpoint of 1 also had favorable sensitivity and specificity for 
detecting moderate risk use of alcohol, tobacco, and marijuana. In contrast, its sensitivity was 
unacceptably low in detecting moderate risk use of stimulants (cocaine, prescription stimulants) 
opioids (heroin, prescription opioids), and sedatives.  One likely reason for this finding is that 
participants who report current abstinence but have experienced certain problems in the past 
(concern expressed by friends or relatives, and failed attempts to control, cut down, or stop 
using) can still score in the moderate risk range on the ASSIST. In contrast, participants who did 
not use the substance in the past 3 months would have a zero score on the TAPS Tool. A 
moderate risk score on the ASSIST in the face of no recent drug use might prove confusing to 
primary care providers because it includes people who may be at risk for using as well as those 
who are using and have some use-related problems. Thus, a potential benefit of the ASSIST-Lite 
and the TAPS Tool is that only recent (past 3 month) use garners any score. Notwithstanding its 
low sensitivity for detecting moderate risk of certain drugs, a score of 1 should prompt providers 
to conduct further assessment of their patient’s use of these substances 
Opioid misuse is a growing problem in the US (Compton et al., 2016) and elsewhere 
(Degenhardt et al., 2014). Patients who misuse prescription opioids may switch to heroin because 
of its lower price (Mars et al., 2014). Primary care practices provide a potentially rich venue in 
which to identify patients misusing opioids. In the present study, 181 (9%) of participants were 
identified with moderate or higher opioid risk scores on the ASSIST and 39 (2%) had a high-risk 
opioid score. At a cutpoint of 2 (i.e., identifying participants with high risk opioid use scores), 
the TAPS Tool had a sensitivity of 0.92, specificity of 0.99, PPV of 0.59, NPV of 1.0, and AUC 
of 0.95. Although these results should be interpreted with some caution because of the relatively 
small sample size, it would be prudent to carefully assess patients with a TAPS Tool score of 2 
for the need for opioid treatment. 
In the present study, the mean time required to complete the TAPS Tool was 4.47 for the 
computer self-administered version, and 2.39 minutes for the interviewer-administered version. 
This compares favorably to the length of time required for the interviewer-administered ASSIST, 
which has been reported to require between 5 and 15 minutes (Ali et al. 2013). It should be noted 
that the time required to administer the TAPS Tool via tablet computer in the present study may 
overestimate the time required in clinical practice, since all participants completed the TAPS-2 
regardless of their responses on TAPS-1. In practice, a patient who reported no illicit drug use on 
the TAPS-1, for example, would not be administered the TAPS-2 items for marijuana, cocaine, 
or heroin. The time required to complete the self-administered TAPS Tool also compared 
favorably to the computer self-administered versions of the ASSIST reported in the literature. In 
the ACASI ASSIST validation study in adult primary care patients, the mean time was 4 
minutes,  (McNeely et al., 2016). Another study of a computer self-administered ASSIST with 
incarcerated men reported that the ACASI ASSIST was completed in 5-10 minutes (Wolff et al., 
2015).   
 The study has a number of strengths, including a large sample size, a diverse population 
recruited from multiple primary care settings across several Eastern US states, and comparison to 
a criterion measure (the ASSIST) that underwent rigorous psychometric testing (Humeniuk et al., 
2008; Newcombe et al., 2005). However, there are also a number of limitations to be considered, 
including sampling only from the Eastern US states, and having only an English language 
version. Hence, findings may not generalize to other parts of the US or to other countries. In 
addition, data were collected under research conditions, and results were not given to medical 
providers.  The extent to which the instrument would perform equally well when delivered by 
primary care staff and entered into the patient’s medical record is not known. Although research 
assistants used a systematic strategy for approaching patients in the clinics’ waiting rooms to 
minimize bias in recruitment, we do not know the extent to which study participants were 
representative of the clinic patient populations.  
 The TAPS Tool has a number of potential advantages compared to other screeners. In 
contrast to single item screens, it inquires about specific substances and goes beyond simple 
endorsement of use by obtaining data on problematic use. It screens for all classes of substances, 
in contrast to single substance screeners such as the AUDIT for alcohol (Bradley et al., 2003) or 
the Fagerstrom for tobacco (Tate & Schmitz, 1993). It is much briefer and easier to score than 
the full ASSIST and can lead to actionable results based on the scores, such that individuals who 
score zero need only receive praise and encouragement and those who score 2 or above need an 
assessment for treatment. The individuals who score 1 would also benefit from further 
assessment, and may be appropriate for brief intervention with prevention messaging and follow-
up. Because the self-administered tablet computer instrument performed as well as the 
interviewer-administered instrument, either approach could be used in primary care practices, 
permitting flexibility and affording the possibility of direct entry into the patient’s medical 
record or self-completion while waiting for the scheduled appointment.  
5. Conclusions 
In comparison to the ASSIST, the TAPS Tool performed well in detecting high risk 
ASSIST scores for all substances and for detecting moderate-risk ASSIST scores for alcohol 
tobacco, and marijuana. It did not perform well in identifying individuals with moderate risk 
ASSIST scores for other drugs. The TAPS Tool score provides the primary care physician with a 
window into current drug use and problems, and is an alternative to the longer version of the 
ASSIST. More research is needed to determine the potential benefits of using the TAPS Tool and 
the ASSIST-lite in different patient populations.  
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Figure 1. TAPS-1 
 
In the past 12 months how often have you: 
 
 used any tobacco product? (for example cigarettes, e-cigarettes, cigars, pipes, or 
smokeless tobacco) 
 had 5 or more drinks (men)/ 4 or more drinks (women) containing alcohol in one day? 
 used any drugs including marijuana, cocaine or crack, heroin, methamphetamine (crystal 
meth), hallucinogens, or ecstasy/MDMA? 
 used any prescription medications just for the feeling, more than prescribed or were not 
prescribed for you? 
o Prescription medications that may be used in this way include 
 Opiate pain reliever (OxyContin, Vicodin, Percocet, Methadone) 
 Medications for anxiety or sleeping (for example: Xanax, Ativan, 
Klonopin) 
 Medications for ADHD (Adderall, Ritalin) 
Response options: Daily or almost daily, Weekly, Monthly, Less than monthly, Never 
 
Figure 2. TAP-2 Items (Yes/No) 
In the past 3 months… 
1. did you smoke a cigarette containing tobacco?   
a. did you usually smoke more than 10 cigarettes each day?  
b. did you usually smoke within 30 minutes after waking?  
2. did you have a drink containing alcohol?  
a. did you have 5 or more drinks* containing alcohol in a day (4 for women)?  
b. have you tried and failed to control, cut down or stop drinking?  
c. has anyone expressed concern about your drinking?  
3. did you use marijuana (hash, weed)?  
a. have you had a strong desire or urge to use marijuana at least once a week or more 
often?  
b. has anyone expressed concern about your use of marijuana?  
4. did you use cocaine or methamphetamine (crystal meth)?  
a. did you use cocaine or methamphetamine (crystal meth) at least once a week or more 
often?  
b. has anyone expressed concern about your use of cocaine or methamphetamine (crystal 
meth)?  
5. did you use heroin?  
a. have you tried and failed to control, cut down or stop using heroin?  
b. has anyone expressed concern about your use of heroin?  
6. did you use a prescription opiate pain reliever (for example, Percocet, Vicodin) not as 
prescribed or that was not prescribed for you?  
a. have you tried and failed to control, cut down or stop using an opiate pain reliever?  
b. has anyone expressed concern about your use of an opiate pain reliever?  
7. did you use a medication for anxiety or sleep (for example, Xanax, Ativan, or Klonopin) not 
as prescribed or that was not prescribed for you?  
a. have you had a strong desire or urge to use medications for anxiety or sleep at least 
once a week or more often?  
b. has anyone expressed concern about your use of medication for anxiety or sleep?  
8. did you use a medication for ADHD (for example, Adderall, Ritalin) not as prescribed or that 
was not prescribed for you?  
a. did you use a medication for ADHD (for example, Adderall, Ritalin) at least once a 
week or more often?  
b. has anyone expressed concern about your use of a medication for ADHD (for example, 
Adderall or Ritalin)?  
9. did you use any other illegal or recreational drug (for example, ecstasy/molly, GHB, poppers, 
LSD, mushrooms, special K, bath salts, synthetic marijuana ('spice'), whip-its, etc.)?  
 what were the other drug(s) you used?  
Note: A “No” response to any substance category item 1 through 8, stops further questions 
about that particular substance and requires moving on to the next substance category item. 
Each “Yes” response garners one point for a possible total score of three points for each 
substance category except for alcohol which can garner a total score of four points. Item 9 is not 
scored.  
 Table 1: Demographic characteristics of participants (N=2,000) 
Characteristic  
 N (%) 
Gender (n/%)  
      Male 874 (43.7%) 
      Female 1124 
(56.2%) 
      Other/Refused 2 (0.1%) 
Age (years)   
      Mean (SD) 46.0 (14.7) 
Ethnicity (n/%)  
      Hispanic  233 (11.7%) 
      Non-Hispanic 1761 
(88.1%) 
      Other/Refused 6 (0.3%) 
Race (n/%)  
      White 667 (33.4%) 
      African-American 1112 
(55.6%) 
      Asian 35 (1.8%) 
      Multiracial 66 (3.3%) 
      Other/Unknown/American Indian or Alaska Native 113 (5.7%) 
      Refused 7 (0.4%) 
 
 Table 2. ASSIST Scores Frequencies, Categories of Use, Means (SD) 
 
Lifetime Use  
 
N (%) 
Past 3-
month Use  
 
N (%) 
Low Risk Moderate 
Risk 
High Risk Mean  
Substance       
Tobacco 1474 (73.7%) 840 (42.0%) 1099 (55.0%) 786 (39.3%) 1015 (5.8%) 8.09 
Alcohol 1793 (89.7%) 1078 
(53.9%) 
1717 (85.9%) 214 (10.7) 69 (93.5%) 5.15 
Illicit Drugs 1325 (66.3%) 470 (23.5%) 1624 (81.2%) 349 (17.5%) 27 (1.4%) 4.24 
Prescription Drugs 612 (30.6%) 163 (8.2%) 1738 (86.9%) 229 (11.5%) 33 (1.7%) 1.77 
By Drug Class       
Marijuana 1257 (62.9%) 350 (17.5%) 1624(81.2%) 349 (17.5%) 27 (1.4%) 2.60 
Illicit Stimulants 754 (37.7%) 129 (6.5%) 1738 (86.9) 229 (11.5%) 33 (1/7%) 1.74 
Heroin 407 (20.4%) 106 (5.3%) 1818 (90.9%) 142 (7.1%) 39 (2.0%) 1.41 
Prescription Opioids 407 (20.4%) 106 (5.3%) 1818 (90.9%) 142 (7.1%) 39 (2.0%) 1.41 
Sedatives 329 (16.5%) 80 (4.0%) 1908 (95.4%) 84 (4.2%) 8 (0.4%) 0.61 
Prescription Stimulants 361 (18.1%) 33 (1.7%) 1944 (97.2%) 52 (2.6%) 4 (0.2%) 0.38 
Other Drugs 404 (20.2%) 37 (1.9%) 1953 (97.7%) 42 (2.1%) 5 (0.3%) 0.32 
Combined Categories       
Opioids (Heroin and 
Prescription Opioids) 
407 (20.4%) 106 (5.3%) 1818 (90.9%) 142 (7.1%) 39 (2.0%) 1.41 
Stimulants (Cocaine, 
Methamphetamine, and 
Prescription Stimulants) 
754 (37.7%) 129 (6.5%) 1738 (86.9%) 229 (11.5%) 33 (1.7%) 1.74 
Illicit Drugs Other than 
Marijuana 
831 (41.6%) 223 (11.2%) 1649 (82.5%) 288 (14.4%) 62 (3.1%) 2.57 
 Table 3.  Interviewer-administered TAPS Tool v. ASSIST (N=2,000) 
 Positive 
on 
ASSIST 
N (%) 
Positive on 
TAPS 
N (%) 
Sensitivity 
(95 % 
Wilson Score 
CI)1 
Specificity 
(95 % 
Wilson 
Score CI) 
PPV2 
(95 % 
Wilson 
Score 
CI) 
NPV3 
(95 % 
Wilson 
Score 
CI) 
AUC4 
High Risk on the ASSIST5 (TAPS Cut-Point = 2) 
Tobacco  115 (0.06) 533 (0.27) 0.90 (0.83, 
0.94) 
0.77 (0.75, 
0.79) 
0.20 
(0.17, 
0.24) 
0.99 
(0.98, 
0.99) 
0.84 
Alcohol 69 (0.03) 449 (0.22) 0.87 (0.77, 
0.93) 
0.80 (0.78, 
0.82) 
0.13 
(0.10, 
0.16) 
0.99 
(0.98, 
0.99) 
0.83 
Marijuana 27 (0.01) 190 (0.10) 0.96 (0.81, 
0.99) 
0.92 (0.91, 
0.93) 
0.14 
(0.10, 
0.20) 
1.00 
(1.00, 
1.00) 
0.94 
Cocaine, 
meth  
33 (0.02) 76 (0.04) 0.94 (0.80, 
0.98) 
0.98 (0.97, 
0.99) 
0.41 
(0.31, 
0.52) 
1.00 
(1.00, 
1.00) 
0.96 
Rx 
stimulant 
4  (0.00) 5 (0.00) 0.25 (0.05, 
0.70) 
1.00 (1.00, 
1.00) 
0.20 
(0.04, 
0.62) 
1.00 
(1.00, 
1.00) 
0.62 
Total 
Stimulants 
(Cocaine, 
meth & Rx 
stimulant) 
33 (0.02) 80 (0.04) 0.94 (0.80, 
0.98) 
0.98 (0.97, 
0.99) 
0.39 
(0.29, 
0.50) 
1.00 
(1.00, 
1.00) 
0.96 
Heroin 39 (0.02) 46 (0.02) 0.82 (0.67, 
0.91) 
0.99 (0.98, 
0.99) 
0.70 
(0.56, 
0.81) 
1.00 
(1.00, 
1.00) 
0.91 
Rx opioids 39 (0.02) 29 (0.01) 0.41 (0.27, 
0.57) 
0.99 (0.98, 
0.99) 
0.55 
(0.37, 
0.71) 
0.99 
(0.98, 
0.99) 
0.70 
Total 39 (0.02) 61 (0.03) 0.92 (0.79, 0.99 (0.98, 0.59 1.00 0.96 
Opioids 
(heroin & 
Rx opioids) 
0.97) 0.99) (0.46, 
0.70) 
(1.00, 
1.00) 
Sedative 8 (0.00) 35 (0.02) 0.63 (0.31, 
0.87) 
0.98 (0.97, 
0.99) 
0.14 
(0.06, 
0.29) 
1.00 
(1.00, 
1.00) 
0.80 
Moderate Risk6 or Higher on the ASSIST (TAPS Cut-Point = 1) 
Tobacco  901 (0.45) 778 (0.39) 0.83 (0.80, 
0.85) 
0.97 (0.96, 
0.98) 
0.96 
(0.94, 
0.97) 
0.87 
(0.85, 
0.89) 
0.90 
Alcohol 283 (0.14) 679 (0.34) 0.83 (0.78, 
0.87) 
0.74 (0.72, 
0.76) 
0.34 
(0.31, 
0.38) 
0.96 
(0.95, 
0.97) 
0.78 
Marijuana 375 (0.19) 317 (0.16) 0.71 (0.66, 
0.75) 
0.97 (0.96, 
0.98) 
0.84 
(0.80, 
0.88) 
0.93 
(0.92, 
0.94) 
0.84 
Cocaine, 
meth 
262 (0.13) 102 (0.05) 0.36 (0.30, 
0.42) 
1.00 (1.00, 
1.00) 
0.92 
(0.85, 
0.96) 
0.91 
(0.90, 
0.92) 
0.68 
Rx 
stimulant 
56 (0.03) 12 (0.01) 0.09 (0.04, 
0.19) 
1.00 (1.00, 
1.00) 
0.42 
(0.20, 
0.68) 
0.97 
(0.96, 
0.98) 
0.54 
Total 
Stimulants 
(Cocaine, 
meth & Rx 
stimulant) 
262 (0.13) 111 (0.06) 0.37 (0.31, 
0.43) 
0.99 (0.98, 
0.99) 
0.87 
(0.79, 
0.92) 
0.91 
(0.90, 
0.92) 
0.68 
Heroin 181 (0.09) 60 (0.03) 0.31 (0.25, 
0.38) 
1.00 (1.00, 
1.00) 
0.93 
(0.84, 
0.97) 
0.94 
(0.93, 
0.95) 
0.65 
Rx opioids 181 (0.09) 70 (0.04) 0.28 (0.22, 
0.35) 
0.99 (0.98, 
0.99) 
0.73 
(0.62, 
0.82) 
0.93 
(0.92, 
0.94) 
0.64 
Total 
Opioids 
(heroin & 
181 (0.09) 109 (0.05) 0.48 (0.41, 
0.55) 
0.99 (0.98, 
0.99) 
0.79 
(0.70, 
0.86) 
0.95 
(0.94, 
0.96) 
0.73 
Notes.   Rx=prescription, meth=methamphetamine. AUC for alcohol moderate risk or higher for 
a cut-off of 2 = 0.80. 
1 Wilson Score CI = Wilson Score Confidence Intervals  
2 PPV = Positive Predictive Value 
3 NPV = Negative Predictive Value 
4 AUC = Area Under the Curve 
5 High Risk on the ASSIST for tobacco, alcohol and all drugs > 27. 
6 Moderate Risk on the ASSIST for tobacco and all drugs = 4 – 26; Moderate Risk for alcohol = 
11-26. 
Rx opioids) 
Sedative 92 (0.05) 55 (0.03) 0.47 (0.37, 
0.57) 
0.99 (0.98, 
0.99) 
0.78 
(0.65, 
0.87) 
0.97 
(0.96, 
0.98) 
0.73 
 Table 4. Self-administered computerized TAPS Tool v. ASSIST (N=2,000) 
 Positive 
on 
ASSIST 
N (%) 
Positive 
on 
TAPS 
N (%) 
Sensitivity 
(95 % 
Wilson 
Score CI)1 
Specificity 
(95 % 
Wilson 
Score CI) 
PPV2 
(95 % 
Wilson 
Score 
CI) 
NPV3 
(95 % 
Wilson 
Score 
CI) 
AUC4 
High Risk on the ASSIST5 (TAPS Cut-Point = 2) 
Tobacco  115 
(0.06) 
539 
(0.27) 
0.90 
(0.83, 
0.94) 
0.77 (0.75, 
0.79) 
0.19 
(0.16, 
0.23) 
0.99 
(0.98, 
0.99) 
0.83 
Alcohol 69 
(0.03) 
470 
(0.24) 
0.91 
(0.82, 
0.96) 
0.79 (0.77, 
0.81) 
0.13 
(0.10, 
0.16) 
1.00 
(1.00, 
1.00) 
0.85 
Marijuana 27 
(0.01) 
190 
(0.10) 
0.96 
(0.81, 
0.99) 
0.92 (0.91, 
0.93) 
0.14 
(0.10, 
0.20) 
1.00 
(1.00, 
1.00) 
0.94 
Cocaine, meth  33 
(0.02) 
81 
(0.04) 
0.91 
(0.77, 
0.97) 
0.97 (0.96, 
0.98) 
0.37 
(0.27, 
0.48) 
1.00 
(1.00, 
1.00) 
0.94 
Rx stimulant 4  
(0.00) 
10 
(0.01) 
0.25 
(0.05, 
0.70) 
1.00 (1.00, 
1.00) 
0.10 
(0.02, 
0.40) 
1.00 
(1.00, 
1.00) 
0.62 
Total 
Stimulants 
(Cocaine, meth 
& Rx 
stimulant) 
33 
(0.02) 
88 
(0.04) 
0.91 
(0.77, 
0.97) 
0.97 (0.96, 
0.98) 
0.34 
(0.25, 
0.44) 
1.00 
(1.00, 
1.00) 
0.94 
Heroin 39 
(0.02) 
47 
(0.02) 
0.79 
(0.64, 
0.89) 
0.99 (0.98, 
0.99) 
0.66 
(0.52, 
0.78) 
1.00 
(1.00, 
1.00) 
0.89 
Rx opioids 39 
(0.02) 
41 
(0.02) 
0.59 
(0.43, 
0.73) 
0.99 (0.98, 
0.99) 
0.56 
(0.41, 
0.70) 
0.99 
(0.98, 
0.99) 
0.79 
Total Opioids 39 67 0.92 0.98 (0.97, 0.54 1.00 0.95 
(heroin & Rx 
opioids) 
(0.02) (0.03) (0.79, 
0.97) 
0.99) (0.42, 
0.65) 
(1.00, 
1.00) 
Sedative 8 (0.00) 55 
(0.03) 
0.75 
(0.41, 
0.93) 
0.98 (0.97, 
0.99) 
0.11 
(0.05, 
0.22) 
1.00 
(1.00, 
1.00) 
0.86 
Moderate Risk of Higher on the ASSIST6 (TAPS Cut-Point = 1) 
Tobacco  900 
(0.45) 
766 
(0.38) 
0.81 
(0.78, 
0.83) 
0.97 (0.96, 
0.98) 
0.96 
(0.94, 
0.97) 
0.86 
(0.84, 
0.88) 
0.89 
Alcohol 283 
(0.14) 
713 
(0.36) 
0.84 
(0.79, 
0.88) 
0.72 (0.70, 
0.74) 
0.33 
(0.30, 
0.37) 
0.97 
(0.96, 
0.98) 
0.78 
Marijuana 376 
(0.19) 
312 
(0.16) 
0.70 
(0.65, 
0.74) 
0.97 (0.96, 
0.98) 
0.85 
(0.81, 
0.89) 
0.93 
(0.92, 
0.94) 
0.84 
Cocaine, meth 262 
(0.13) 
112 
(0.06) 
0.39 
(0.33, 
0.45) 
0.99 (0.98, 
0.99) 
0.90 
(0.83, 
0.94) 
0.91 
(0.90, 
0.92) 
0.69 
Rx stimulant 56 
(0.03) 
19 
(0.01) 
0.14 
(0.07, 
0.25) 
0.99 (0.98, 
0.99) 
0.42 
(0.23, 
0.64) 
0.98 
(0.97, 
0.99) 
0.57 
Total 
Stimulants 
(Cocaine, meth 
& Rx 
stimulant) 
262 
(0.13) 
124 
(0.06) 
0.40 
(0.34, 
0.46) 
0.99 (0.98, 
0.99) 
0.84 
(0.77, 
0.89) 
0.92 
(0.91, 
0.93) 
0.69 
Heroin 181 
(0.09) 
59 
(0.03) 
0.31 
(0.25, 
0.38) 
1.00 (1.00, 
1.00) 
0.95 
(0.86, 
0.98) 
0.94 
(0.93, 
0.95) 
0.65 
Rx opioids 181 
(0.09) 
81 
(0.04) 
0.28 
(0.22, 
0.35) 
0.98 (0.97, 
0.99) 
0.62 
(0.51, 
0.72) 
0.93 
(0.92, 
0.94) 
0.63 
Total Opioids 
(heroin & Rx 
opioids) 
181 
(0.09) 
113 
(0.06) 
0.44 
(0.37, 
0.51) 
0.98 (0.97, 
0.99) 
0.70 
(0.61, 
0.78) 
0.95 
(0.94, 
0.96) 
0.71 
Sedative 92 81 0.52 0.98 (0.97, 0.59 0.98 0.75 
Notes. Rx= prescription. Meth=methamphetamine. Cut-off of 1 on high risk ASSIST score for 
select substances as follows: cocaine/methamphetamine = 0.96; total stimulants = 0.96; heroin = 
0.93; prescription opioids = 0.895; total opioids = 0.98.  Cut off of 2 on moderate risk or higher 
ASSIST score for alcohol = 0.81. 
 1 Wilson Score CI = Wilson Score Confidence Intervals  
2 PPV = Positive Predictive Value 
3 NPV = Negative Predictive Value 
4 AUC = Area Under the Curve 
5 High Risk on the ASSIST for tobacco, alcohol and all drugs > 27. 
6 Moderate Risk on the ASSIST for tobacco and all drugs = 4 – 26; Moderate Risk for alcohol = 
11-26 
*  Tobacco n = 900 (in contrast to Table 2 in which n = 901) because of missing data. 
 
 
(0.05) (0.04) (0.42, 
0.62) 
0.99) (0.48, 
0.69) 
(0.97, 
0.99) 
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